

THIS IS ONLY PUBLIC ADVERTISEMENT FOR INFORMATION PURPOSES AND NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE FOR SECURITIES.
NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



(Please scan this QR code to view the Red Herring Prospectus)

CHANDAN HEALTHCARE LIMITED

Our Company was incorporated as a public limited Company under the name “Chandan Healthcare Limited”, under the provisions of the Companies Act, 1956 and Certificate of Incorporation was issued by the Registrar of Companies, U.P. & Uttaranchal, Kanpur on September 03, 2003. For details of incorporation, change of name and registered office of our Company, please refer to chapter titled “General Information” and “History and Certain Corporate Matters” beginning on page 75 and 191 respectively of the Red Herring Prospectus.

Registered office and Corporate Office: Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow- 226021, Uttar Pradesh, India; **Tel:** +91 8429024430; **E-mail:** secretarial@chandan.co.in; **Website:** www.chandandiagnostics.com
Contact Person: Rajeev Nain, Company Secretary & Compliance Officer; **Corporate Identity Number:** U85110UP2003PLC193493

OUR PROMOTERS: AMARANITA HOLDINGS (INDIA) PRIVATE LIMITED, AMAR SINGH, ASMITA SINGH, ALOK SINGH, SHALEEN SOLANKI, VIJAY SINGH AND VINAY LAMBA

THE OFFER IS BEING MADE INACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF NSE (EMERGE PLATFORM OF NSE OR NSE)

THE OFFER

INITIAL PUBLIC OFFERING OF UP TO 67,52,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH (“EQUITY SHARES”) OF CHANDAN HEALTHCARE LIMITED (“COMPANY” OR THE “ISSUER”) FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) (“OFFER PRICE”) AGGREGATING UP TO ₹ [•] LAKHS COMPRISING A FRESH ISSUE OF UP TO 44,52,064 EQUITY SHARES AGGREGATING UP TO ₹ [•] LAKHS BY OUR COMPANY (“FRESH ISSUE”) AND AN OFFER FOR SALE OF UP TO 22,99,936 EQUITY SHARES AGGREGATING UP TO ₹ [•] LAKHS (THE “OFFERED SHARES”) COMPRISING OF UP TO 17,54,936 EQUITY SHARES BY AMARANITA HOLDINGS (INDIA) PRIVATE LIMITED, UP TO 1,10,000 EQUITY SHARES BY JAGJEET SINGH KALSI, UP TO 1,00,000 EQUITY SHARES BY DEEPAK KUMAR SIROHI, UP TO 50,000 EQUITY SHARES BY AJAI SINGH, UP TO 50,000 EQUITY SHARES BY BIMLA SINGH, UP TO 50,000 EQUITY SHARES BY VIKAS LAMBA, UP TO 50,000 EQUITY SHARES BY ANCHAL SIROHI, UP TO 50,000 EQUITY SHARES BY HARI SHANKER DIXIT, UP TO 50,000 EQUITY SHARES BY SHITAL SINGH SOLANKI, UP TO 25,000 EQUITY SHARES BY VIKALP DIXIT AND UP TO 10,000 EQUITY SHARES BY BRAHM PRAKASH AGGREGATING UP TO ₹ [•] LAKHS (THE “SELLING SHAREHOLDERS” AND SUCH OFFER, THE “OFFER FOR SALE”) (THE “OFFER FOR SALE” AND TOGETHER WITH THE FRESH ISSUE, THE “OFFER”) OF WHICH 3,39,200 EQUITY SHARES AGGREGATING TO ₹ [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE OFFER (THE “MARKET MAKER RESERVATION PORTION”). THE OFFER INCLUDES A RESERVATION OF UP TO 2,45,600 EQUITY SHARES, AGGREGATING UP TO ₹ [•] LAKHS, FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (AS DEFINED HEREIN) NOT EXCEEDING [•]% OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL (“EMPLOYEE RESERVATION PORTION”). THE OFFER, LESS EMPLOYEE RESERVATION AND MARKET MAKER RESERVATION, I.E. NET OFFER [•] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT PRICE OF ₹ [•] PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE “NET OFFER”. OUR COMPANY AND THE SELLING SHAREHOLDERS MAY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER, OFFER A DISCOUNT UP TO ₹ [•] OF THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION (“EMPLOYEE DISCOUNT”). THE OFFER AND THE NET OFFER WILL CONSTITUTE 27.61% AND 25.22% RESPECTIVELY OF THE FULLY-DILUTED POST- OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE FACE VALUE OF EQUITY SHARES IS ₹ 10 EACH. THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES.

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE PRICE PER EQUITY SHARE

Name of Selling Shareholders	Type	Maximum number of Offered Shares	Weighted average cost of acquisition per Equity Share (In ₹)*
Amaranita Holdings (India) Private Limited	Promoter Selling Shareholder	Up to 17,54,936	10
Jagjeet Singh Kalsi	Investor Selling Shareholder	Up to 1,10,000	10
Deepak Kumar Sirohi	Investor Selling Shareholder	Up to 1,00,000	10
Ajai Singh	Promoter group Selling Shareholder	Up to 50,000	10
Bimla Singh	Promoter group Selling Shareholder	Up to 50,000	3.43
Vikas Lamba	Promoter group Selling Shareholder	Up to 50,000	10
Shital Singh Solanki	Promoter group Selling Shareholder	Up to 50,000	10
Anchal Sirohi	Investor Selling Shareholder	Up to 50,000	10
Hari Shanker Dixit	Investor Selling Shareholder	Up to 50,000	10
Vikalp Dixit	Investor Selling Shareholder	Up to 25,000	10
Brahm Prakash	Investor Selling Shareholder	Up to 10,000	10

*As certified by M/s MSNT & Associates LLP, Chartered Accountants, Statutory and Peer Review Auditor by way of their certificate dated February 04, 2025

Our Company: We run a diagnostic network in North India with pathology and radiology testing services. Our test menu includes (a) 481 routine pathology tests, covering basic biochemistry and hematology, as well as 1,015 specialized pathology tests, such as immohistopathology, and molecular pathology, and (b) 545 radiology tests, including basic x-rays, ultrasonography (“USG”), computed tomography (“CT”), magnetic resonance imaging (“MRI”), and specialized CT scans

The Offer is being made in accordance with regulation 229(2) of the SEBI ICDR regulations

QIB CATEGORY: NOT MORE THAN 50% OF THE NET OFFER
NON-INSTITUTIONAL INVESTOR CATEGORY: NOT LESS THAN 15% OF THE NET OFFER
RETAIL CATEGORY: NOT LESS THAN 35% OF THE NET OFFER
MARKET MAKER PORTION: UPTO 3,39,200 EQUITY SHARES OR 5.02% OF THE OFFER.
EMPLOYEE RESERVATION PORTION: UP TO 2,45,600 EQUITY SHARES AGGREGATING UP TO ₹ [•] LAKHS

PRICE BAND: ₹ 151 TO ₹ 159 PER EQUITY SHARE OF FACE VALUE OF ₹ 10 EACH.

THE FLOOR PRICE 15.10 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 15.90 TIMES OF THE FACE VALUE.

BIDS CAN BE MADE FOR A MINIMUM OF 800 EQUITY SHARES AND IN MULTIPLES OF 800 EQUITY SHARES THEREAFTER.

RISKS TO INVESTORS:

i.The average cost of acquisition per Equity Share by our Promoters is set forth in the table below:

Name of the Promoters	No. of shares held	Average Cost of Acquisition (in ₹)
Amaranita Holdings (India) Private Limited	58,43,000	10
Amar Singh	23,19,860	10.52
Asmita Singh	1,62,000	10
Alok Singh	3,00,000	2.38
Shaleen Solanki	9,00,000	10
Vijay Singh	8,99,400	10
Vinay Lamba	15,84,800	10

and the Offer price at the upper end of the price band is ₹ 159 per Equity Share.

ii.Weighted Average Cost of Acquisition for all Equity Shares transacted in one year, eighteen months and three years preceding the date of the Red Herring Prospectus by all the shareholders:

Period	Weighted Average Cost of Acquisition (in ₹) [#]	Upper end of the Price band ₹ 159 is ‘X’ times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price - Highest Price (in ₹)
Last 1 year	10.28	15.47	₹ 0 - ₹ 16
Last 18 months	10.28	15.47	₹ 0 - ₹ 16
Last 3 years	6.72	23.66	₹ 0 - ₹ 16

#As certified by our Statutory and Peer Review Auditor, by way of their certificate dated February 04, 2025.

iii.The Price/Earnings ratio based on diluted EPS for Fiscal 2024 for our Company at the upper end of the Price Band is 19.53 times.

iv.Weighted Average Return on Net Worth for fiscals 2024, 2023 and 2022 is 23.10%

v.The Weighted average cost of acquisition compared to floor price and cap price.

Past Transactions	Weighted average cost of acquisition (₹)	Floor Price ₹ 151	Cap Price ₹ 159
WACA of Primary Offer (except for bonus Offer)	NA	NA	NA
WACA for Secondary sale/ acquisitions not exceeding 5% of the pre-Offer capital	NA	NA	NA
WACA average cost of acquisition of past primary issuances / secondary in last 3 years.	6.72	22.47	23.66

vi. Any interruptions at our flagship diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.

vii. Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.

viii.The BRLM associated with the Offer have handled 21 public issues in the past three years, out of which one issue closed below the issue price on listing date.

Investors should read the RHP carefully, including the “Risk Factors” on page 42 of the RHP before making any investment decision.

BASIS FOR ISSUE PRICE

The Price Band will be determined by our Company in consultation with the BRLM. The Offer Price will be determined by our Company, in consultation with the BRLM, on the basis of assessment of market demand for the Equity Shares offered in the offer through the Book Building Process and on the basis of the qualitative and quantitative factors as described below. The face value of the Equity Shares is ₹ 10 each and the Offer Price is 15.10 times the face value at the lower end of the Price Band and 15.90 times the face value at the higher end of the Price Band. Investors should also refer to “Our Business”, “Risk Factors”, “Financial Statements” and “Management’s Discussion and Analysis of Financial Position and Results of Operations” on pages 165, 42, 234, and 292, respectively, of the RHP to have an informed view before making an investment decision.

Qualitative factors

Some of the qualitative factors which form the basis for computing the Offer Price are:

- Strong Geographical presence in Uttarakhand.
- Integrated diagnostics provider with one-stop solution offering pathology and radiology testing, and medical consultation services.
- Track record of profitability and consistent financial performance.
- Dedicated management team with significant industry experience.

For further details, see “Our Business - Our Competitive Strength” on page 175 of the RHP.

Quantitative factor

Some of the information presented below relating to our Company is derived from the Restated Consolidated Financial Statements.

Some of the quantitative factors which may form the basis for calculating the Offer Price are as follows:

1. Basic and diluted earnings per share (“EPS”)

Year ended	Basic/Diluted EPS (in ₹)	Weight
Fiscal 2024	8.14	3
Fiscal 2023	1.68	2
Fiscal 2022	(0.55)	1
Weighted Average	4.54	
For the period ended December 31, 2024*	8.07	

*Not annualized

Continue From Next Page...

...Continue From Previous Page

Notes:

- Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. sum of (EPS x Weight) for each year /Total of weights.
- Basic and diluted EPS are based on the Restated Consolidated Financial Statement.
- The face value of each Equity Share is ₹10.
- Earnings per Share (₹) = Profit after tax excluding exceptional items attributable to equity shareholders for the year/period divided by the weighted average no. of equity shares during the respective year/period. ;
- Earnings per Share calculations are in accordance with the notified Accounting Standard 20 'Earnings per share'.
- The figures disclosed above are based on the Restated Consolidated Financial Statements.

II. Price/Earning ("P/E") ratio in relation to Price Band of ₹ 151 to ₹ 159 per Equity Share:

Particulars	P/E at the Floor Price (number of times)*	P/E at the Cap Price (number of times)*
P/E ratio based on Basic EPS for Fiscal 2024	18.55	19.53
P/E ratio based on Diluted EPS for Fiscal 2024	18.55	19.53

*To be updated at Prospectus stage.

Note: Price / earning (P / E) ratio is computed by dividing the price per share by earnings per share.

Industry Peer Group P/E ratio

Particulars	Industry P/E (Number of times)
Industry	
Highest	87.75
Lowest	62.34
Average	75.05

Notes:

- The industry high and low has been considered from the industry peer set provided later in this section. The industry composite has been calculated as the arithmetic average P / E of the industry peer set disclosed in this section.
- P/E Ratio has been computed based on the closing market price of equity shares on the NSE website on January 30, 2025 divided by the Diluted EPS for the period ended March 31, 2024.
- All the financial information for listed industry peers mentioned above is sourced from the audited financial statements of the relevant companies for Fiscal 2024, as available on the websites of the Stock Exchanges.

III. Return on Net Worth ("RoNW")

Derived from the Restated Financial Statements:

Fiscal	RoNW %	Weight
Fiscal 2024	39.54%	3
Fiscal 2023	12.31%	2
Fiscal 2022	(4.62) %	1
Weighted Average	23.10%	
For the period ended December 31, 2024*	29.74%	

* Not Annualised

Notes:

- RoNW = Net Profit after tax, as restated divided by Net-worth, as restated (Net worth include share capital and reserves and surplus)
- The figures disclosed above are based on the Restated Consolidated Financial Statements of our Company.
- Return on Net Worth (%) = Restated Profit/(loss) attributable to owners of the holding company/ net worth at the end of the year
- Net-worth, as restated at the end of the relevant period (Equity attributable to the owners of the company, excluding minority interest)

IV. Net asset value per Equity Share (face value of ₹ 10 each)

Net Asset Value per Equity Share derived from the Restated Financial Statements:

Particulars	Amount
Net Asset Value per Equity Share for the period ended December 31, 2024*	27.15
Net Asset Value per Equity Share as of March 31, 2024	20.58
After completion of the Offer	
(i) At Floor price	44.97
(ii) At Cap Price	46.46
Offer Price per equity share	[*]

* Not Annualised

Notes:

- Net Asset Value per Equity Share is calculated as total equity divided by weighted average number of equities shares outstanding during the respective year/period.

V. Comparison with listed industry peer:

Following is the comparison with our peer companies listed in India:

Name of The Company	For the year ended March 31, 2024						
	Face value (₹)	Revenue from operations (₹ in lakhs)	Basic EPS (₹)	Diluted EPS (₹)	P/E (based on Diluted EPS)	Return on net worth (%)	NAV per (₹)
Chandan Healthcare Limited	10	17,659.01	8.14	8.14	[*]	39.54%	20.58
Peer Group							
Vijaya Diagnostic Ltd	1	54,780.53	11.62	11.59	87.75	19.91%	64.21
Dr. Lal Pathlabs Ltd	10	2,22,664.10	46.25	46.18	62.34	20.61%	221.61
Metropolis Healthcare Ltd	2	1,20,770.88	24.95	24.87	72.18	12.33%	214.01

Source: All the financial information for listed industry peers mentioned above is on a consolidated basis (If applicable) sourced from the Annual Reports of the peer company uploaded on the NSE website for the year ended March 31, 2024.

Notes:

- P/E Ratio has been computed based on the closing market price of equity shares on the NSE website on January 30, 2025 divided by the Diluted EPS for the period ended March 31, 2024.
 - RoNW is computed as net profit after tax divided by the net worth. Net worth has been computed as sum of share capital and reserves and surplus.
 - NAV is computed as the closing net worth divided by the closing outstanding number of equity shares.
- Investors should read the above mentioned information along with "Risk Factors", "Our Business", Management Discussion and Analysis of Financial Position and Results of Operations" and "Financial Information" on pages 42, 165, 292 and 234, respectively, to have a more informed view. The trading price of the Equity Shares could decline due to the factors mentioned in the "Risk Factors" and you may lose all or part of your investments.

VI. Key financial and operational performance indicators ("KPIs")

The KPIs disclosed below have been used historically by our Company to understand and analyse the business performance, which in result, help us in analysing the growth of various verticals.

Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilisation of the proceeds of the Fresh Offer as per the disclosure made in the Objects of the Issue Section, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations.

KPI	Explanations
Revenue from Operations (₹ lakhs)	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps assess the overall financial performance of our Company and size of our business.
Total Revenue	Total Revenue is used to tack the total revenue generated by the business including other income.
EBITDA (₹ lakhs)	EBITDA provides information regarding the operational efficiency of the business.
EBITDA Margin (%)	EBITDA Margin is an indicator of the operational profitability and financial performance of our business.
Profit After Tax (₹ lakhs)	Profit after tax provides information regarding the overall profitability of the business.
PAT Margin	PAT Margin is an indicator of the overall profitability and financial performance of our business.
RoE (%)	RoE provides how efficiently our Company generates profits from shareholders' funds.
Debt To Equity Ratio	Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage.
Interest Coverage Ratio	The interest coverage ratio is a debt and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Return on Capital employed (RoCE) (%)	It is calculated as profit before tax plus finance costs divided by total assets plus current liabilities.
Current Ratio	It tells management how business can maximize the current assets on its balance sheet to satisfy its current debt and other payables.
Net Capital Turnover Ratio	This metric enables us to track the how effectively company is utilizing its working capital to generate revenue.

The KPIs disclosed below have been approved by a resolution of our Audit Committee dated January 30, 2025 and the members of the Audit Committee have verified the details of all KPIs pertaining to the Company. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three-year period prior to the date of filing of the RHP. Further, the KPIs herein have been certified by MSNT & Associates LLP Chartered Accountants, by their certificate dated February 01, 2025.

VII. Financial KPI of our Company

Metric	For the period ended August 31, 2024	As of and for the Fiscal		
	2024	2023	2022	
Revenue From operations (₹ in Lakhs)	16,747.47	17,659.01	13,688.94	11,956.35
Total income (₹ in Lakhs)	16,798.82	17,795.86	13,702.92	11,991.58
EBITDA (₹ in Lakhs)	3,009.12	2,610.27	927.41	215.75
EBITDA Margin (%)	34.85%	14.78%	6.77%	1.80%
Profit after tax (₹ in Lakhs)	1,741.99	1,635.50	358.63	(109.25)
PAT Margin (%)	10.40%	9.26%	2.62%	(0.91%)
Return on Equity (ROE) (%)	33.83%	47.50%	13.11%	(4.64%)
Debt To Equity Ratio	0.96	1.02	0.78	0.69
Interest Coverage Ratio	18.52	10.01	4.01	1.34
Return on Capital Employed (ROCE) (%)	27.17%	35.20%	15.61%	1.34%
Current Ratio	1.03	1.05	0.95	0.96
Net Capital Turnover Ratio	53.78	709.91	(54.65)	(68.86)

Notes:

- As certified by MSNT & Associates LLP, Chartered Accountants pursuant to their certificate dated Febuary 01, 2025. The Audit committee in its resolution dated January 30, 2025 has confirmed that the Company has not disclosed any KPIs to any investors at any point of time during the three years preceding the date of this Red Herring Prospectus other than as disclosed in this section.
- Revenue from Operations means the Revenue from Operations as appearing in the Restated Consolidated Financial Statements.
- EBITDA refers to earnings before interest, taxes, depreciation, amortisation, gain or loss from discontinued operations and exceptional items. EBITDA excludes other income but includes reversal of provision of doubtful debts.
- EBITDA Margin refers to EBITDA during a given period as a percentage of revenue from operations during that period.

- Net Profit Ratio/Margin quantifies our efficiency in generating profits from our revenue and is calculated by dividing our net profit after taxes but before other comprehensive income by our revenue from operations.
- Return on equity (RoE) is equal to profit after tax for the year divided by the total equity during that period and is expressed as a percentage.
- Debt to equity ratio is calculated by dividing the debt (excluding lease liabilities) by total equity (which includes issued capital and all other equity reserves).
- Interest Coverage Ratio measures our ability to make interest payments from available earnings and is calculated by dividing EBITDA by finance cost payment.
- RoCE (Return on Capital Employed) (%) is calculated as profit before tax plus finance costs divided by total assets plus current liabilities.
- Current Ratio is a liquidity ratio that measures our ability to pay short-term obligations (those which are due within one year) and is calculated by dividing the current assets by current liabilities.
- Net Capital Turnover Ratio quantifies our effectiveness in utilizing our working capital and is calculated by dividing our revenue from operations by our working capital (i.e., current assets less current liabilities).

See "Management Discussion and Analysis of Financial Position and Results of Operations" on page 292 for the reconciliation and the manner of calculation of our key financial performance indicators.

VIII.Comparison of financial KPIs of our Company and our listed peer.

Metric	Chandan Healthcare Ltd	Vijaya Diagnostic Centre Ltd	Dr Lal Pathlabs Ltd	Metropolis Healthcare Ltd
	Fiscal 2024			
Revenue From operations (₹ in Lakhs)	17,659.01	54,780.53	2,22,664.10	1,20,770.88
Total income (₹ in Lakhs)	17,795.86	56,862.33	2,29,580.60	1,21,682.58
EBITDA (₹ in Lakhs)	2,610.27	21,884.89	60,924.20	28,257.55
EBITDA Margin (%)	14.78%	39.95%	27.36%	23.40%
Profit after tax (₹ in Lakhs)	1,635.50	11,963.71	36,229.30	12,845.56
PAT Margin (%)	9.26%	21.84%	16.27%	10.64%
Return on Equity (ROE) (%)	47.50%	19.91%	20.61%	12.33%
Debt To Equity Ratio	1.02	0.39	0.05	0.00
Interest Coverage Ratio	10.01	9.12	20.75	12.54
Return on Capital Employed (ROCE) (%)	35.20%	21.38%	27.89%	18.23%
Current Ratio	1.05	2.90	2.42	1.28
Net Capital Turnover Ratio	709.77	3.15	3.82	22.42

Metric	Chandan Healthcare Ltd	Vijaya Diagnostic Centre Ltd	Dr Lal Pathlabs Ltd	Metropolis Healthcare Ltd
	Fiscal 2023			
Revenue From operations (₹ in Lakhs)	13,688.94	45,922.27	2,01,688.20	1,14,821.02
Total income (₹ in Lakhs)	13,702.92	47,337.34	2,05,860.10	1,16,343.48
EBITDA (₹ in Lakhs)	927.41	18,202.73	48,983.40	28,829.59
EBITDA Margin (%)	6.77%	39.64%	24.29%	25.11%
Profit after tax (₹ in Lakhs)	358.63	8,520.70	24,107.70	14,339.40
PAT Margin (%)	2.62%	18.55%	11.95%	12.49%
Return on Equity (ROE) (%)	13.11%	16.82%	15.22%	15.30%
Debt To Equity Ratio	0.78	0.45	0.14	0.08
Interest Coverage Ratio	4.01	8.69	13.05	10.76
Return on Capital Employed (ROCE) (%)	15.61%	18.62%	20.34%	19.38%
Current Ratio	0.95	4.17	2.07	1.14
Net Capital Turnover Ratio	(54.65)	2.22	4.59	17.76

Metric	Chandan Healthcare Ltd	Vijaya Diagnostic Centre Ltd	Dr Lal Pathlabs Ltd	Metropolis Healthcare Ltd
	Fiscal 2022			
Revenue From operations (₹ in Lakhs)	11,956.35	46,236.99	2,08,740.80	1,22,833.60
Total income (₹ in Lakhs)	11,991.58	47,520.05	2,13,995.40	1,24,595.90
EBITDA (₹ in Lakhs)	215.74	20,369.01	56,072.50	35,869.29
EBITDA Margin (%)	1.80%	44.05%	26.86%	29.20%
Profit after tax (₹ in Lakhs)	(109.26)	11,066.76	35,029.10	21,468.61
PAT Margin (%)	-0.91%	23.93%	16.78%	17.48%
Return on Equity (ROE) (%)	-4.64%	26.76%	25.51%	26.96%
Debt To Equity Ratio	0.69	0.39	0.23	0.29
Interest Coverage Ratio	1.34	12.38	18.58	18.17
Return on Capital Employed (ROCE) (%)	1.34%	28.45%	32.67%	33.82%
Current Ratio	0.96	4.08	1.75	1.30
Net Capital Turnover Ratio	(68.86)	2.32	3.35	4.95

Notes:

- Revenue from Operations means the Revenue from Operations as appearing in the Restated Consolidated Financial Statements.
- EBITDA refers to earnings before interest, taxes, depreciation, amortisation, gain or loss from discontinued operations and exceptional items. EBITDA excludes other income but includes reversal of provision of doubtful debts.
- EBITDA Margin refers to EBITDA during a given period as a percentage of revenue from operations during that period.
- Net Profit Ratio/Margin quantifies our efficiency in generating profits from our revenue and is calculated by dividing our net profit after taxes by our revenue from operations.
- Return on equity (RoE) is equal to profit for the year divided by the total equity during that period and is expressed as a percentage.
- Debt to equity ratio is calculated by dividing the debt (i.e., borrowings (current and non-current) and current maturities of long-term-borrowings) by total equity (which includes issued capital and all other equity reserves).
- Interest Coverage Ratio measures our ability to make interest payments from available earnings and is calculated by dividing cash profit after tax plus interest payment by interest payment.
- RoCE (Return on Capital Employed) (%) is calculated as profit before tax plus finance costs divided by total assets plus current liabilities.
- Current Ratio is a liquidity ratio that measures our ability to pay short-term obligations (those which are due within one year) and is calculated by dividing the current assets by current liabilities.
- Net Capital Turnover Ratio quantifies our effectiveness in utilizing our working capital and is calculated by dividing our revenue from operations by our working capital (i.e., current assets less current liabilities).
- Return on Net Worth (RoNW) is a measure of profitability (expressed in percentage) and is defined as net profit after tax attributable to our equity shareholders divided by our Net Worth (total shareholders' equity) for the year. "Net Worth" is defined as the aggregate of share capital and other equity.

** All the information for listed industry peer mentioned above is on a consolidated basis and is sourced from their respective audited.

IX. Weighted average cost of acquisition ("WACA"), floor price and cap price

Primary Transactions:

There has been no primary / new issue of shares (equity/convertible securities), excluding shares issued under ESOP/ESOS and issuance of bonus shares, during the 18 months preceding the date of filing of the RHP where such issuance is equal to or more than 5 per cent of the fully diluted paid-up share capital of the Issuer Company (calculated based on the pre-issue capital before such transaction/s and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Secondary Acquisition:

There have been no secondary sale/transfers or acquisition of any Equity Shares or convertible securities, where the Promoters, members of the Promoter Group, the Selling Shareholders or Shareholders having the right to nominate Directors to the Board of our Company are a party to the transaction (excluding gifts), during the 18 months preceding the date of this Red Herring Prospectus, where either acquisition or sale is equal to or more than 5% of the fully diluted paid up share capital of our Company (calculated based on the pre-issue capital before such transaction(s) and excluding employee stock options granted but not vested), in a single transaction or multiple transactions combined together over a span of rolling 30 days.

Since there are no such transactions to report to under (a) and (b) therefore, information based on last five primary or secondary transactions (secondary transactions where our Promoters/ members of our Promoter Group or Shareholder(s) having the right to nominate director(s) in the Board of our Company, are a party to the transaction), during the three years prior to the date of this Draft Red Herring Prospectus irrespective of the size of transactions, is as below

Secondary Transactions								
Date of Transfer	Name of Transferor	Name of Transferee	No. of Securities	Face value of Securities	Price of securities (₹)	Nature of transaction	Nature of consideration	Total Consideration (in ₹ lakhs)
March 14, 2023	Virendra Singh	Bimla Singh	2,47,005	10	-	Gift	Other than Cash	-
March 20, 2024	Suresh Babu	Amar Singh	2,00,000	10	16	Transfer	Other than Cash	32,00,000
March 20, 2024	Suresh Babu	Rajeev Nain	1,00,000	10	16	Transfer	Other than Cash	16,00,000
March 31, 2024	Sandeep Solanki	Adity Solanki	1,00,000	10	-	Transfer	Other than Cash	-
March 31, 2024	Ragi Lochan	Rajeev Lochan	67,000	10	-	Transfer	Other than Cash	-
Weighted average cost of acquisition (WACA)								6.72

Floor price and cap price being 14.83 and 15.61 times the weighted average cost of acquisition (WACA) based on primary/ secondary transaction(s) as disclosed in terms of clause (a) and (b) or Note 1 above, shall be disclosed in the following manner:

Past Transactions	Weighted average cost of acquisition (₹)	Floor Price 151	Cap Price 159
WACA of Equity Shares that were issued by our Company	NA	NA	NA
WACA of Equity Shares that were acquired or sold by way of secondary transactions	NA	NA	NA
Since there were no Primary Transactions or Secondary Transactions to report under points (a) and (b) above, during the 18 months preceding the date of filing of this Red Herring Prospectus, the information has been disclosed for price per share of our Company based on the last five primary or secondary transactions not older than three years prior to the date of this Red Herring Prospectus irrespective of the size of the transaction			
- Based on Primary Transactions	NA	NA	NA
- Based on Secondary Transactions	6.72	22.47	23.66

X. Justification for Basis of Offer Price

Explanation for Offer Price / Cap Price being 15.61 times of weighted average cost of acquisition of primary issuance price / secondary transaction price of Equity Shares along with our Company's KPIs and financial ratios for year ended on March 31, 2022, March 31, 2023 and March 31, 2024 and for the period ended December 31, 2024.

- Our company has a strong presence across Uttarakhand, with a network spanning 19 tier-two cities and towns. This extensive reach enables us to provide high-quality diagnostic services to a diverse population, from urban centers like Dehradun to remote villages. With 12 centers strategically located near major medical institutions and commercial hubs, we ensure greater accessibility, convenience, and service efficiency for our patients.
- As of December 31, 2024, we offer a comprehensive range of 1,496 tests across various specialties, including 481 routine pathology tests covering basic biochemistry and hematology, along with 1,015 specialized pathology tests such as immunohistopathology and molecular pathology. Additionally, we provide 545 radiology tests, ranging from basic X-rays and ultrasonography (USG) to advanced imaging techniques like computed tomography (CT), magnetic resonance imaging (MRI), and specialized CT scans. Our radiology facilities are equipped with eleven CT scanners and four MRI machines, ensuring high-quality diagnostic services. For the period ending December 2024, product sales contributed 47.00% of our total revenue, while pathology and radiology services accounted for 34.22% and 18.77%, respectively.
- Over the past three fiscal years and for the period ending December 31, 2024, we have experienced steady growth in our financial performance. Our revenue from operations increased from ₹ 11,956.35 lakhs in Fiscal 2022 to ₹ 13,688.94 lakhs in Fiscal 2023, reaching ₹ 17,659.01 lakhs in Fiscal 2024 and ₹ 16,747.47 lakhs for the period ended December 31, 2024. This consistent growth is driven by our focus on increasing sales, enhancing efficiency, and improving productivity.
- Our success is driven by a team of seasoned professionals with diverse and complementary expertise, essential for navigating the fast-growing Indian diagnostic market. Backed by extensive experience in the healthcare industry, our management team has played a pivotal role in our significant growth. Under their leadership, we have consistently improved the productivity and efficiency of our network over the years.

For Further details see the chapter titled "Basis for Offer Price" beginning on page 146 of the RHP.

Continue From Next Page...

BID/OFFER PROGRAMME

ANCHOR INVESTOR BID/ OFFER PERIOD: FRIDAY, FEBRUARY 07, 2025*

BID/OFFER OPENS ON: MONDAY, FEBRUARY 10, 2025

BID/OFFER CLOSES ON: WEDNESDAY, FEBRURAY 12, 2025**

* Our Company in consultation with the BRLM, may consider participation by Anchor Investors, in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Offer Opening Date.

**Our Company in consultation with the BRLM, may decide to close the Bid/Offer Period for QIBs one Working Day prior to the Bid/Offer Closing Date, in accordance with the SEBI ICDR Regulations.


***UPI Mandate end time and date shall be at 5:00 pm, on bid/offer closing date.

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid /Offer Period for a minimum of one Working Day, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the respective websites of the BRLM and at the terminals of the members of the Syndicate and by intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“**SCRR**”) read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“**QIBs**”) (the “**QIB Portion**”), provided that our Company in consultation with the BRLM may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis (“**Anchor Investor Portion**”). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) (“**Net QIB Portion**”). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35.00% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount (“**ASBA**”) process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“**SCSBs**”) or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see “*Offer Procedure*” on page 386.

Bidders / Applicants should ensure that DP ID, PAN and Client ID and UPI ID (for RIBs bidding through the UPI mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidder/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to an Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020, and press release dated June 25, 2021.

ASBA*	Simple, safe, smart way of Application!!!!	*Applications supported by blocked amount (ASBA) is a better way of applying to offers by simply blocking the fund in the bank account. For further details, check section on ASBA below. Mandatory in Public offers. No cheque will be accepted.
--------------	---	---



Upl- Now available in ASBA for all individual investors applying in public Offers where the application amount is up to ₹ 5,00,000, applying through Registered Brokers, Syndicate, CDPs & RTAs. UPI-Now mandatory in ASBA for Retail Individual Bidders (“RIBs”) applying through Registered Brokers, DPs & RTA. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.
Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021.
**ASBA has to be availed by all the investors. UPI may be availed by Retail Individual Bidders.*
*For details on the ASBA and UPI process, please refer to the details given in ASBA Form & abridged prospectus and also please refer to the section “Offer Procedure” beginning on page 386 of the RHP. The process is also available on the website of AIIB and Stock Exchange in the General information Document. ASBA Forms can be downloaded from the NSE Limited (“**NSE**”) and can be obtained from the list of banks that is displaying on website of SEBI at www.sebi.gov.in. List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. For the list of UPI Apps and Banks live on IPO, please refer to the link: [www.sebi.gov.in.Kotak](http://www.sebi.gov.in/Kotak) Mahindra Bank Limited has been appointed as Sponsor Bank for the Offer in accordance with the requirements of the SEBI Circular dated November 1, 2018, as amended. For UPI related queries, investors can contact NPCI at the toll-free number: 18001201740 and mail Id: ipo.upi@npci.org.in*

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF OUR COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see “*History and Certain Corporate Matters*” on page 191 of the RHP. The Memorandum of Association of our Company is a material document for inspection in relation to the Offer. For further details, see the section “*Material Contracts and Documents for Inspection*” on page 447 of the RHP.

LIABILITY OF MEMBERS OF THE COMPANY: Limited by shares.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The authorized share capital of the Company is ₹ 25,00,00,000 divided into 2,50,00,000 Equity Shares of ₹ 10 each. The Offered, subscribed, and paid-up share capital of the Company before the Offer is ₹ 20,00,00,000 divided into 2,00,00,000 Equity Shares of ₹ 10 each. For details of the Capital Structure, see chapter titled “*Capital Structure*” beginning on page 87 of the RHP.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed by them at the time of signing of the Memorandum of Association of our Company: Amar Singh (10,000 Equity Shares); Virendra Singh (10,000 Equity Share); Vishal Lamba (10,000 Equity Shares); Vikas Lamba (5,000 Equity Shares); Ajay Singh (5,000 Equity Shares); Asmita Singh (5,000 Equity Shares); Anita Singh (2,000 Equity Shares); Vinay Lamba (1,000 Equity Shares); Shaleen Solanki (1,000 Equity Shares) and Mahabir Prasad Jain (1,000 Equity Shares) of ₹10 each.

LISTING: The Equity Shares Offered through the Red Herring Prospectus are proposed to be listed on the Emerge Platform of NSE Limited (“**NSE EMERGE**”) in terms of the Chapter IX of the SEBI (ICDR) Regulations, as amended from time to time. Our Company has received an approval letter dated January 14, 2025, from NSE for using its name in the Offer Document for listing of our shares on the Emerge Platform of NSE. For the purpose of this Offer, the Designated Stock Exchange will be the NSE.

DISCLAIMER CLAUSE OF SECURITIES AND EXCHANGE BOARD OF INDIA (“SEBI”): Since the Offer is being made in terms of chapter IX of the SEBI (ICDR) Regulations, 2018, the Red Herring Prospectus has been filed with SEBI. In terms of the SEBI Regulations, the SEBI shall not Offer any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire Disclaimer Clause of SEBI beginning on page 361 of the Red Herring Prospectus.

DISCLAIMER CLAUSE OF NSE (“NSE EMERGE”) (THE DESIGNATED STOCK EXCHANGE): It is to be distinctly understood that the permission given by NSE should not in any way be deemed of construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 363 of the RHP for the full text of the Disclaimer Clause of NSE.

TRACK RECORD OF BOOK RUNNING LEAD MANAGER: The Merchant Banker associated with the Offer has handled 10 main board public issues and 11 SME public issues in the past three financial years.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer including the risks involved. The Equity Shares Offered in the Offer have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section titled “*Risk Factors*” beginning on page 42 of the Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE OFFER	COMPANY SECRETARY & COMPLIANCE OFFICER
 <p>UNISTONE CAPITAL PRIVATE LIMITED A/305, Dynasty Business Park Andheri-Kurla Road, Andheri East, Mumbai - 400 059. Telephone: 022 4604 6494 Email: mb@unistonecapital.com Investor grievance email: compliance@unistonecapital.com Contact Person: Brijesh Parekh; Website: www.unistonecapital.com SEBI registration number: INM000012449 CIN: U65999MH2019PTC330850</p>	 <p>KFin Technologies Limited Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500 032, Telangana Telephone: +91 40 6716 2222 Email: chl.ipo@kfintech.com Investor grievance email: einward.ris@kfintech.com Contact Person: M Murali Krishna; Website: www.kfintech.com SEBI Registration Number: INR000000221</p>	<p>Rajeev Nain, Chandan Healthcare Limited Biotech Park, Sector G, Jankipuram, Kursi Road, Lucknow- 226021, Uttar Pradesh, India Telephone: +91 8429024430 Website: www.chandandiagnostic.com Email id: secretarial@chandana.co.in</p> <p>Investors can contact the Company Secretary and Compliance Officer, BRLM or the Registrar to the Offer in case of any pre- Offer or post Offer related problems, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode.</p>

AVAILABILITY OF RHP: Investors should note that investment in Equity Shares involves a high degree of risk and investors are advised to refer to the Red Herring Prospectus and the Risk Factor contained therein, before applying in the Offer. Full copy of the Red Herring Prospectus shall be available at the website of Stock Exchange www.nseindia.com, the website of Book Running Lead Manager www.unistonecapital.com and from the Registered Office of the Company.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the **Company: Chandan Healthcare Limited** (Telephone: +91 8429024430) **BRLM: Unistone Capital Private Limited** (Telephone: 022-4604 6494) **Syndicate Member: R.K. Stockholding Private Limited** (Telephone: 011-48564444), Registered Brokers, RTA and CDPs participating in the Offer. Bid-cum-application Forms will also be available on the websites of, NSE (www.nseindia.com) and the designated branches of SCSBs, the list of which is available at websites of the Stock Exchange and SEBI.

SYNDICATE MEMBER: R.K. Stockholding Private Limited

BANKERS TO THE OFFER/ SPONSOR BANK / ESCROW COLLECTION BANK / PUBLIC OFFER BANK / REFUND BANK: ICICI Bank Limited

UPI: UPI Bidders can also Bid through UPI Mechanism

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

For CHANDAN HEALTHCARE LIMITED
On Behalf of the Board of Directors

Sd/-

Amar Singh

Chairman & Managing Director

Place: Lucknow

Date: February 04, 2025.

CHANDAN HEALTHCARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares and has filed the RHP with Registrar of Companies on February 04, 2025. The RHP shall be available on the website of the BRLM to the Offer at www.unistonecapital.com and websites of NSE i.e. www.nseindia.com. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled “*Risk Factors*” beginning on page 42 of the RHP. Potential investors should not rely on the DRHP for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”) or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any applicable U.S. state securities laws. There will be no public offering in the United States and the securities being offered in this announcement are not being offered or sold in the United States.